

UiPath Stock (PATH): The AI Automation Comeback
Investors Should Be Watching in 2026 Can UiPath turn the agentic AI revolution into accelerating growth? A deep dive into its latest earnings, financial outlook, strategic partnerships, valuation, risks, and upcoming catalysts. TradeFables Equity Research | October 22, 2026 | NYSE: PATH The Big Question: Is UiPath Becoming More Important in the Age of AI? Artificial intelligence is changing the way businesses operate. But while investors have spent years focusing on the compa


Theranos and Elizabeth Holmes The Billion-Dollar Blood Test Fraud That Fooled Silicon Valley
The promise sounded simple enough to change medicine: a few drops of blood from a finger prick, hundreds of tests, fast results, lower cost, and no needles in the arm. Theranos sold that promise with rare force. Its founder, Elizabeth Holmes, became the face of a new kind of health start-up, one that borrowed the language of Silicon Valley speed and applied it to clinical diagnostics. Investors saw a company that could reshape blood testing. Retail partners saw walk-in clinic




























